PDL BioPharma Announces Second Quarter 2017 Financial Results
INCLINE VILLAGE, Nev., Aug. 3, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today reported financial results for the second quarter ended June 30, 2017 including:
Total revenues of $143.8 million and $189.3 million for the three and six months ended June 30, 2017, respectively.v GAAP diluted EPS of $0.39 and $0.42 for the three and six months ended June 30, 2017, respectively.
GAAP net income attributable to PDL's shareholders of $60.4 million and $67.7 million for the three and six months ended June 30, 2017, respectively.
Total revenues of $143.8 million and $189.3 million for the three and six months ended June 30, 2017, respectively.v GAAP diluted EPS of $0.39 and $0.42 for the three and six months ended June 30, 2017, respectively.
GAAP net income attributable to PDL's shareholders of $60.4 million and $67.7 million for the three and six months ended June 30, 2017, respectively.